Skip to Main Content

Paper Details

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Breast Cancer Res Treat
3
2023
Author NameAffiliation
Chris TwelvesUniversity of Leeds and St James' Hospital
John M S BartlettUniversity of Edinburgh
Tammy PiperUniversity of Edinburgh
  • 1 - 3

Datasets

Release 1.2